Britain’s public health agency says preliminary data suggest that people with the omicron variant of the coronavirus are between 50% and 70% less likely to need hospitalization than those with
LONDON — A third dose of both the AstraZeneca and Pfizer-BioNTech COVID-19 vaccines significantly increased the immune response to the omicron variant, according to a new study by University of
Britain s public health agency says preliminary data suggest that people with the omicron variant of the coronavirus are between 50% and 70% less likely to need hospitalization than those with the delta strain.